Amgen announced Monday that the FDA has accepted its supplemental Biologics License Application for denosumab.
Amgen announced Monday that the FDA has accepted its supplemental Biologics License Application (sBLA) for denosumab (XGEVA). The application seeks to expand the monoclonal antibody’s currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The FDA set a Prescription Drug User Fee Act action date of February 3, 2018.
Amgen’s sBLA, submitted in April, is based on the data gathered in a phase 3, randomized, double-blind, multicenter study that met its primary endpoint of demonstrating non-inferiority of denosumab to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma. The study did not meet its secondary endpoints of demonstrating superiority of denosumab in time to first on-study skeletal-related event and delaying time to first-and-subsequent skeletal-related event.
“Multiple myeloma patients with fractures and other bone complications have a very poor prognosis,” says Sean E. Harper, MD, executive vice president of research and development at Amgen. “Bisphosphonates are the only approved class of agents for the prevention of skeletal-related events in this patient population,” he went on, citing kidney toxicity and acute phase reaction as potential adverse events related to treatment with bisphosphonates. “We look forward to potentially making XGEVA available as a novel option for patients with multiple myeloma,” Harper said.
Multiple myeloma is the second most common hematologic cancer, developing in plasma cells located in the bone marrow microenvironment. This cancer is typically characterized by osteolytic bone lesions and renal impairment. While over 90% of patients with multiple myeloma develop osteolytic lesions during the course of the disease, bisphosphonates are cleared by the kidneys and are associated with renal toxicity. Approximately 60% of patients with multiple myeloma have or will develop renal impairment over the course of the disease.
As denosumab is not cleared by the kidneys, it may provide an opportunity to prevent bone complications—responsible for significant morbidity in patients with multiple myeloma—without increased renal complications.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.